Risk/benefit in prophylaxis and treatment of secondary hyperparathyroidism. A comparison of two low calcium peritoneal dialysis fluids | Zendy

Susanne Bro | Zendy; Lisbet Brandi | Zendy; Klaus Ølgaard | Zendy

Open Access

Risk/benefit in prophylaxis and treatment of secondary hyperparathyroidism. A comparison of two low calcium peritoneal dialysis fluids

Author(s) -

Susanne Bro,

Lisbet Brandi,

Klaus Ølgaard

Publication year - 1996

Publication title -

nephrology dialysis transplantation

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.654

H-Index - 168

eISSN - 1460-2385

pISSN - 0931-0509

DOI - 10.1093/ndt/11.supp3.47

Subject(s) - medicine , alfacalcidol , peritoneal dialysis , hypercalcaemia , secondary hyperparathyroidism , dialysis , hyperparathyroidism , calcium , gastroenterology , hemodialysis , endocrinology , liter , urology , parathyroid hormone , osteoporosis , bone mineral

A comparison of (i) levels of plasma ionized calcium (Ca), phosphate (P) and iPTH, (ii) risk of hypercalcaemia and (iii) need for Al-containing P binders, in patients on CAPD treated with calcium carbonate as the main P binder and twice weekly oral doses of alfacalcidol for control of secondary hyperparathyroidism during a 1 year follow-up after switching from a dialysis fluid with a Ca concentration of 1.75 mmol/l to 1.25 mmol/l (n = 39) or 1.35 mmol/l (n = 37).

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research